{
 "meta": {
  "api_version": "1.0.0",
  "dataset_version": "2.0.1",
  "corpus_snapshot": "2026-10-12T22:59:14+0200",
  "source_commit": "93739c9d195dc39e47eecfabc3cab2565a2f256f",
  "license": "CC-BY-4.0",
  "cite": "Barton O. Oliver's mTOR Atlas. doi:10.5281/zenodo.22059963",
  "docs": "https://mtor-atlas.org/api/"
 },
 "data": {
  "id": "RAPA-LONGEVITY",
  "claim": "Rapamycin activates Longevity",
  "source": {
   "name": "Rapamycin",
   "entity": "rapamycin"
  },
  "target": {
   "name": "Longevity",
   "entity": "longevity"
  },
  "effect": "activates",
  "type": "functional-consequence",
  "directness": "indirect",
  "timescale": "chronic",
  "compartment": null,
  "map_band": "outcome",
  "species": [
   "mouse"
  ],
  "mechanism": "Rapamycin extends lifespan in genetically heterogeneous mice even when started late in life - one of the most influential results in the geroscience arm of this Atlas.",
  "mechanism_beginner": "Rapamycin makes mice live longer, even when given late in life – the single biggest result behind the whole \"this pathway and ageing\" idea.",
  "context": null,
  "boundary": "Mouse only. No human lifespan or healthspan endpoint exists; EVERLAST has no results yet. BIT2016 shows a non-continuous schedule can still extend post-treatment life expectancy, but the result is dose- and route-specific: in the 8 mg/kg/day intraperitoneal arm males gained +60% post-treatment life expectancy (p=0.02) while females showed no survival benefit (p=0.261) and a shift toward aggressive haematopoietic cancers (16/16 vs 6/12, p=0.002); in the same paper's 126 ppm dietary encapsulated-rapamycin arm survival rose significantly in BOTH sexes, with a Cox model finding no evidence that sex modified the treatment effect (p=0.904). Cite the arm, not just the paper. ARR2016: an intermittent regimen (2 mg/kg every 5 days) started as late as 20 months of age extended lifespan in female C57BL/6J mice; the abstract reports the effect in females only.",
  "note": "ARR2015 was removed from this edge on 2026-07-29: that study measured side effects only and has no survival endpoint.",
  "consensus_contested": false,
  "curation_contested": false,
  "contested": false,
  "confidence": {
   "mechanistic": "medium",
   "human_relevance": "untested",
   "consensus": "established"
  },
  "evidence": {
   "kind": "Pharmacological",
   "strongest": {
    "code": "A",
    "label": "Animal model"
   },
   "supporting": [
    "HAR2009",
    "BIT2016",
    "KHA2014",
    "CHE2009",
    "ARR2016"
   ],
   "conflicting": []
  },
  "external_refs": [],
  "reviewed": null,
  "updated": null,
  "checked": null,
  "review_status": "unreviewed",
  "reviewer": null,
  "curation_status": "Proposed",
  "url": "https://mtor-atlas.org/relation/RAPA-LONGEVITY/",
  "api_url": "https://mtor-atlas.org/api/v1/relations/RAPA-LONGEVITY.json"
 }
}